moomoo ID:NaN
Log Out
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
CNTB Connect Biopharma
Post Mkt Price
Do not show
Hide blank lines
Total revenue
0 0 0
Operating revenue
-- 0 -- 0 -- 0
Cost of revenue
Gross profit
Operating expense
224.25% 621.47M 69.18% 191.66M 113.29M
Selling and administrative expenses
156.59% 122.45M 391.30% 47.72M -- 9.71M
-General and administrative expense
156.59% 122.45M 391.30% 47.72M -- 9.71M
Research and development costs
243.21% 518.02M 41.83% 150.93M -- 106.41M
Other operating expenses
-171.80% -19M -146.44% -6.99M -- -2.84M
Operating profit
-224.25% -621.47M -69.18% -191.66M -113.29M
Net non-operating interest income expense
126.56% 578K -314.81% -2.18M 1.01M
Non-operating interest income
-13.25% 622K -32.74% 717K -- 1.07M
Non-operating interest expense
4.76% 44K -20.75% 42K -- 53K
Total other finance cost
-- -- -- 2.85M -- --
Other net income (expense)
-16.89% -684.24M -938.89% -585.39M -56.35M
Gain on sale of security
52.90% -2.87M -300.00% -6.1M -- 3.05M
Other non- operating income (expenses)
-17.62% -681.36M -875.28% -579.29M -- -59.4M
Income before tax
-67.49% -1.31B -362.11% -779.23M -168.63M
Income tax
1.7M 0 0
Net income
-67.71% -1.31B -362.11% -779.23M -168.63M
Net income continuous Operations
-67.71% -1.31B -362.11% -779.23M -- -168.63M
Minority interest income
Net income attributable to the parent company
-67.71% -1.31B -362.11% -779.23M -168.63M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-67.71% -1.31B -362.11% -779.23M -168.63M
Basic earnings per share
-79.08% -25 -362.09% -13.96 -3.0211
Diluted earnings per share
-79.08% -25 -362.09% -13.96 -3.0211
Dividend per share
Currency Unit
Accounting Standards
Audit Opinions
Unqualified OpinionUnqualified Opinion--

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Connect Biopharma Holdings Ltd. engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. Its lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma. The company was founded by Zheng Wei and Wu Bin Pan on November 23, 2015 and is headquartered in Taicang, China.
CEO: Dr. Zheng Wei, PhD
Market: NASDAQ
Listing Date: 03/19/2021
Hot List
SymbolLatest price%Chg